Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2551-2557

  Erdlenbruch, Bernhard ^a   Jendrossek, Verena ^a   Marx, Maike ^a   Hunold, Andrea ^a   Eibl, Hansjörg ^b   Lakomek, Max ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Antitumor effect; Brain tumor chemotherapy; C6 cells; Erucylphosphocholine (ErPC); Glioblastoma cells; Rat brain tumor model

Indexed keywords

ANTINEOPLASTIC AGENT; EDELFOSINE; MILTEFOSINE; PHOSPHORYLCHOLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS TISSUE TUMOR; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; CELL SURVIVAL; GLIOBLASTOMA; GLIOMA; HUMANS; KINETICS; MALE; PHOSPHORYLCHOLINE; RATS; RATS, WISTAR; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031810795     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Baumann WJ, Berdel WE, van den Bosch H, Eibl H, Herrmann DBJ. Munder PG, Snyder FL and Unger C (eds): First international symposium on ether lipids in oncology. Lipids 22: 787-974, 1987.
2. Andreesen R, Modolell M, Weltzien HU, Eibl H, Common HH, Lohr GW and Munder PG: Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 38: 3894-3899, 1978.
3. Berdel WE, Bausert WER, Fink U, Rastetter J and Munder PG: Antitumor action of alkyllysophospholipids (review). Anticancer Res 1: 345-352, 1981.
4. Arnold B, Reuther R and Weltzien HU: Distribution and metabolism of synthetic alkyl analogs of lysophosphatidylcholine in mice. Biochim Biophys Acta 530: 47-55, 1978.
5. Kötting J, Marschner NW, Neumüller W, Unger C, and Eibl H: Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholinc: A comparison of hemolytic activity, serum binding and tissue distribution. In: Alkylphosphocholines: New drugs in cancer therapy (Eibl H, Hilgard P and Unger C, eds.) Prog Exp Tumor Res 34: Karger-Verlag, Basel, pp 131-142, 1992.
6. Eibl H and Unger C: Hexadecylphosphocholine, a new and selective antitumor drug. Cancer treatment reviews 17: 233-242, 1990.
7. Kaufmann-Kolle P, Drevs J, Berger MR, Kötting J, Marschner N, Unger C and Eibl H: Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother Pharmacol 34: 393-398, 1994.
8. Verweij J, Planting A, Van der Burg M and Stoter G: A dose finding study of miltefosine (Hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 118: 606-608, 1992.
9. Planting AST, Stoter G and Verweij J: Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 29 A: 518-519, 1993.
10. Berdel WE, Becher R, Edler L, Bremer K, Essers U, Drozd A. Zafferani M, Klee MAG, Bachmann P, Korfel A and Westerhausen M: Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non-small cell lung cancer. A phase II study. Oncology 15: 238-242, 1992.
11. Kötting J, Berger MR, Unger C and Eibl H: Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol 30: 105-112, 1992.
12. Berger MR, Betsch B, Gebelein M, Amtmann E, Heyl P and Schert HR: Hexadecylphosphocholine differs from conventional cytostatic agents. J Cancer Res Clin Oncol 119: 541-548, 1993.
13. Kaufmann-Kolle P, Kötting J, Drevs V, Berger MR, Unger C and Eibl H. Intravenous application of alkylphosphocholines: Comparison of different homologues in lamellar structures. J Cancer Res Clin Oncol 720 (Suppl): R14, 1992.
14. Eibl H and Kaufmann-Kolle P: Medical application of synthetic phospholipids as liposomes and drugs. J Liposome Res 5(1): 131-148, 1995.
15. Erdlenbruch B, Wolff J, Schmidt G, Eibl H and Lakomek M: Alkylphosphocholines in brain tumor therapy-effects of erucylphosphocholine in an experimental rat glioma model. J Neuro-Oncology 30: 133, 1996.
16. Erdlenbruch B, Jendrossek V, Marx M, Hunold A, Eibl H and Lakomek M: Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo: Anticancer Res 17: 4075-4076.
17. Eibl H and Woolley P: A general synthetic method for enantiomerically pure ester and ether lyso-phospholipids. Chem Phys Lipids 47: 47-53, 1988.
18. Eibl H and Engel J: Synthesis of Hexadecylphosphocholine (Miltefosine). Prog Exp Tumor Res 34: 1-5, 1992.
19. Harms PG and Ojeda SR: A rapid and simple mehod for chronic cannulation of the jugular vein. J Appl Physiol 36: 391-392, 1974.
20. Kötting J, Marschner NW, Unger C and Eibl H: Determination of alkylphosphocholines in biological fluids and tissues In: Alkylphosphocholines: new drugs in caner therapy (Eibl H, Higard P and Unger C, eds). Basel, S Karger, 1992, pp 6-11.
21. Fleer EAM, Kim D-J, Nagel GA, Eibl H and Unger C: Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma raji cells. Oncology 13: 295-300, 1990.
22. 3 and hexadecylphosphocholine against mammary tumors in BD-VI rats. Lipids 22: 927-929, 1987.
23. Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C and Berger M: Characterization of the antitumor activity of hexadecylphosphocholine (D18506). Eur J Clin Oncol 24: 1457-1461, 1988.
24. Unger C, Damenz W and Fleer EAM: Hexadecylphosphocholine, a new etherlipid analogue: studies on the antineoplastic activity in vitro and in vivo. Acta Oncologica 28: 213-217, 1988.
25. Magistrelli A, Villa P, Benfenati E, Modest EJ, Salmona M and Tacconi MT: Fate of 1-O-octadecyl-2-O-Methyl-rac-glycero-3-phosphocholine (ET18-OMe) in malignant cells, normal cells and isolated and perfused rat liver. Drug Metabol Dispos 23: 113-118, 1995.
26. Jendrossek V, Erdlenbruch B, Hunold A, Kugler W, Eibl H and Lakomek M: Erucylphosphocholine, a novel antineoplastic ether lipid efficiently induces growth arrest and apoptosis in brain tumor cell lines in vitro. Int J Cancer, submitted for publication.